Cibinqo
FDA Approved
Description
Abrocitinib is a JAK1 inhibitor for the treatment of atopic dermatitis. It works by blocking the activity of Janus kinase 1 (JAK1), an enzyme involved in inflammation.
Indications & Therapeutic Use
Atopic dermatitis associated with hyper-IgE syndrome
Linked Diseases:
Global Availability (2 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Cibinqo
| Generic Name | Cibinqo |
| Brands | 1 brand available |
| Active Ingredient | Abrocitinib |
| Drug Class | Atopic dermatitis associated with hyper-IgE syndrome |
| Manufacturer | Pfizer |
| Dosage Forms | Tablet |
| Medical Code | L04AA48 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved |
| Countries | 2 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations3 Validated Nodes